| pubmed-article:10875907 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10875907 | lifeskim:mentions | umls-concept:C0153633 | lld:lifeskim |
| pubmed-article:10875907 | lifeskim:mentions | umls-concept:C0005854 | lld:lifeskim |
| pubmed-article:10875907 | lifeskim:mentions | umls-concept:C1883709 | lld:lifeskim |
| pubmed-article:10875907 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:10875907 | pubmed:dateCreated | 2000-8-30 | lld:pubmed |
| pubmed-article:10875907 | pubmed:abstractText | (99m)Tc-Sestamibi (MIBI) has been successfully applied in recurrent glioblastoma. The aim of this study was to evaluate the incremental diagnostic information of MIBI as a tumor-avid radiopharmaceutical compared with (99m)Tc-pertechnetate ((99m)Tc) as sole indicator of the integrity of the blood-brain barrier. Twenty-five patients with confirmed recurrent brain tumors were included. MIBI SPET was performed 10 min after injection of 555 MBq MIBI intravenously with a triple-headed gamma camera equipped with LE-UHR-PAR collimators over 360 degrees (3 degrees /step) and stored in a 128(2) matrix. Identical acquisition parameters were used for (99m)Tc SPET, which was acquired 3 h after injection of 740 MBq (99m)Tc. Normalized tumor uptake (NU) was calculated from attenuation-corrected transaxial slices. In addition, tumor/plexus, tumor/nasopharynx, and tumor/parotid gland ratios were assessed in both studies. No statistically significant differences were detected for the mean NU of tumor tissue with MIBI (0.26 +/- 0.10) and (99m)Tc (0.39 +/- 0. 33) and for the tumor/nasopharynx and tumor/parotid gland ratios; only the tumor/plexus ratio was significantly higher for (99m)Tc than for MIBI (p < 0.05). In conclusion, our data indicate that MIBI scintigraphy in brain tumors at 10 min postinjection reveals no additional visual information over that provided by the conventional (99m)Tc-pertechnetate brain scan, and in addition, tracer retention reflects primarily blood-brain barrier damage. | lld:pubmed |
| pubmed-article:10875907 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10875907 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10875907 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10875907 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10875907 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10875907 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10875907 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10875907 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:10875907 | pubmed:issn | 1053-8119 | lld:pubmed |
| pubmed-article:10875907 | pubmed:author | pubmed-author:HoffmannMM | lld:pubmed |
| pubmed-article:10875907 | pubmed:author | pubmed-author:PuiuAA | lld:pubmed |
| pubmed-article:10875907 | pubmed:author | pubmed-author:MarosiCC | lld:pubmed |
| pubmed-article:10875907 | pubmed:author | pubmed-author:LeithaTT | lld:pubmed |
| pubmed-article:10875907 | pubmed:author | pubmed-author:KillenAA | lld:pubmed |
| pubmed-article:10875907 | pubmed:author | pubmed-author:FazenyBB | lld:pubmed |
| pubmed-article:10875907 | pubmed:author | pubmed-author:StaudenherzAA | lld:pubmed |
| pubmed-article:10875907 | pubmed:author | pubmed-author:NaselCC | lld:pubmed |
| pubmed-article:10875907 | pubmed:copyrightInfo | Copyright 2000 Academic Press. | lld:pubmed |
| pubmed-article:10875907 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10875907 | pubmed:volume | 12 | lld:pubmed |
| pubmed-article:10875907 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10875907 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10875907 | pubmed:pagination | 109-11 | lld:pubmed |
| pubmed-article:10875907 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:10875907 | pubmed:meshHeading | pubmed-meshheading:10875907... | lld:pubmed |
| pubmed-article:10875907 | pubmed:meshHeading | pubmed-meshheading:10875907... | lld:pubmed |
| pubmed-article:10875907 | pubmed:meshHeading | pubmed-meshheading:10875907... | lld:pubmed |
| pubmed-article:10875907 | pubmed:meshHeading | pubmed-meshheading:10875907... | lld:pubmed |
| pubmed-article:10875907 | pubmed:meshHeading | pubmed-meshheading:10875907... | lld:pubmed |
| pubmed-article:10875907 | pubmed:meshHeading | pubmed-meshheading:10875907... | lld:pubmed |
| pubmed-article:10875907 | pubmed:meshHeading | pubmed-meshheading:10875907... | lld:pubmed |
| pubmed-article:10875907 | pubmed:meshHeading | pubmed-meshheading:10875907... | lld:pubmed |
| pubmed-article:10875907 | pubmed:meshHeading | pubmed-meshheading:10875907... | lld:pubmed |
| pubmed-article:10875907 | pubmed:meshHeading | pubmed-meshheading:10875907... | lld:pubmed |
| pubmed-article:10875907 | pubmed:meshHeading | pubmed-meshheading:10875907... | lld:pubmed |
| pubmed-article:10875907 | pubmed:meshHeading | pubmed-meshheading:10875907... | lld:pubmed |
| pubmed-article:10875907 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:10875907 | pubmed:articleTitle | Does (99m)Tc-Sestamibi in high-grade malignant brain tumors reflect blood-brain barrier damage only? | lld:pubmed |
| pubmed-article:10875907 | pubmed:affiliation | Department of Nuclear Medicine, University Hospital of Vienna-AKH, Waehringer-Guertel 18-20, A-1090, Vienna, Austria. | lld:pubmed |
| pubmed-article:10875907 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10875907 | pubmed:publicationType | Comparative Study | lld:pubmed |
